

## Research Article

# Pharmacological Profiling of Suppressive Drugs to Musculoskeletal Tumors

Nakajima K<sup>1,2\*</sup><sup>1</sup>Division of Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Research Institute, Tokyo, Japan<sup>2</sup>Division of Veterinary Oncology and Surgery, Faculty of Veterinary Medicine, Imabari Campus, Okayama University of Science, Japan

**\*Corresponding author:** Kosei Nakajima, Division of Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Research Institute, Tokyo 104-0045, Japan and Division of Veterinary Oncology and Surgery, Faculty of Veterinary Medicine, Imabari Campus, Okayama University of Science, Japan

**Received:** July 06, 2020; **Accepted:** August 06, 2020;**Published:** August 13, 2020**Abstract**

Treatment of aggressive musculoskeletal tumors remains clinically a conundrum, and requires the identification of novel drug that can be therapeutically exploited to improve patient outcome. The emerging genomic study suggested that there may be a core molecular determinant of progression of sarcoma, whereby we hypothesized that a commonly shared effective drugs by targeting the core of musculoskeletal tumors. Here, pharmacological profiling of suppressive drugs was shown using 29 types of patient-derived musculoskeletal tumor cell lines and 164 FDA-approved drugs. The cell line panel was composed of osteosarcoma, Ewing's sarcoma, undifferentiated pleomorphic sarcoma, chondrosarcoma, extraskeletal chondrosarcoma, synovial sarcoma, rhabdomyosarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, clear cell sarcoma, and dermatofibrosarcoma protuberans. Based on cell viability, suppression ratio was determined on each tumor and anti-cancer agent. Then, clustering analysis was performed, and heatmap image were depicted. As a result, a nine drugs were found to be more suppressive drugs than doxorubicin, a standard drug to sarcomas, specifically homoharringtonine, mitoxantrone, and ponatinib potently suppressed the cell viability in a variety of sarcomas regardless of histological subtypes. In conclusion, the new outlook suggests delivering a commonly shared therapeutic umbrella rather than histotype-tailored regimen in musculoskeletal tumors.

**Keywords:** Sarcoma; Musculoskeletal tumor; Malignant

## Introduction

Malignant musculoskeletal tumor originates in bone or soft tissues such as muscle, cartilage, connective tissues and metastatic foci from primary lesion to the skeleton(s) [1,2]. In some cases, they shows wider invasion to the surrounding soft tissues, or metastatic spreading to other parts of the body. To combat the aggressive behavior of malignant musculoskeletal tumors, effective chemotherapeutic drugs associated with tumor shrinkage and longer survival time have been identified, and currently standardized guidelines are available [3-6].

In patients with osteosarcoma, a combination of methotrexate, doxorubicin, cisplatin, and ifosfamide was utilized in clinical settings. As for Ewing's sarcoma, vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and actinomycin-D were currently standard chemotherapeutic drugs. With regard to aggressive soft tissue sarcoma, doxorubicin and ifosfamide were known as key drugs. Recently, pazopanib, trabectedin, and eribulin has been shown the efficacy in clinical trials. In case of rhabdomyosarcoma, the applicable drugs were vincristine, actinomycin-D, cyclophosphamide, ifosfamide, etoposide, irinotecan, topotecan, and doxorubicin. Thus, although a variety of therapeutic agents are now offered, there is unmet medical needs to identify novel drugs to treat chemotherapy-resistant refractory sarcomas, or to target wider variety of histological subtypes in malignant musculoskeletal tumors. Indeed, a randomized phase III clinical trial did not show any superiority of histotype-tailored regimen to standard chemotherapy [7]. Thus, an essential chemotherapy to sarcoma remain a conundrum. The emerging

genomic study suggested that there may be a core molecular determinant of progression of sarcoma [8], whereby we hypothesized that a commonly shared effective drugs by targeting the core of musculoskeletal tumors.

In this study, pharmacological profiling of suppressive drugs was shown using 29 types of patient-derived musculoskeletal tumor cell lines, and commonly effective drugs were identified.

## Material and Method

### Tissue culture

This study was approved by the ethics committee of National Cancer Center. A variety of musculoskeletal tumor tissue obtained at the time of surgical resection was subjected to the cell culture. The excised tumor tissue was minced with scissors, and seeded in a culture dish in a condition of 5% CO<sub>2</sub> at 37° C. The cells were maintained in DMEM or RPMI 1640 medium supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (100 mg/ml).

### Authentication of cell line

Genomic DNA was extracted from the original tissue and cultured cell using DNeasy blood and tissue kits (Qiagen). Then, we examined the analysis of Short Tandem Repeats (STRs) using STR multiplex assays Gene Print 10 (Promega, Madison, WI). The STR analysis included amplification and detection of 10 loci. The amplified products were tested by ABI 3500xL Genetic Analyzer and GeneMapper 5.0 and Peak scanner (Applied Biosystems, Waltham, MA).

## Drug screening

Bravo Automated Liquid Handling Platform was employed for high-throughput screening. The drug panel was composed of 166 FDA-approved anti-cancer agents. The compounds were dissolved in Dimethyl Sulfoxide (DMSO) and adjusted to a final drug concentration of 10  $\mu$ M in culture medium. 1250 cells/well were seeded into 384-well culture plates. On the following day, each anticancer compounds or vehicle control were added. After 72 hours of incubation, cell viability was measured by using a Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc, Japan.), and calculated the suppression rates. Experiments were repeated at least twice.

## Bioinformatics analysis

Heat map analysis was performed by R 3.5.3 software (The R Project for Statistical Computing) and its package software, Complex Heatmap version 1.20.0 [9].

## Results

### Identification of commonly shared suppressive drugs to sarcoma

In order to find commonly suppressive drug to musculoskeletal tumors, we employed 29 patient-derived sarcoma cell lines, including two cell lines of osteosarcoma, one cell line of Ewing's sarcoma, two cell lines of CIC-DUX4 sarcoma, six cell lines of undifferentiated pleomorphic sarcoma, one cell line of chondrosarcoma, two cell lines of extraskeletal chondrosarcoma, two cell lines of synovial sarcoma, two cell lines of rhabdomyosarcoma, two cell lines of leiomyosarcoma, five cell lines of malignant peripheral nerve sheath tumor, three cell lines of clear cell sarcoma, and one cell line of dermatofibrosarcoma protuberans. Based on cell viability, suppression ratio was determined on each tumor and anti-cancer agent. Then, the clustering analysis was performed, and heatmap image were depicted.

In the left side, 164 FDA-approved drugs were listed based on the bioinformatics clustering. The blue color indicates the suppressive effect on tumor proliferation, whereas the red color indicates no efficacy. The top group colored in blue was identified as commonly shared umbrella for inhibitory influences on sarcomas. Since doxorubicin is known as a standard key drug which often utilized in a variety of sarcomas, it was defined as reference line of inhibitory effect. As a result, top cluster of the heatmap included more suppressive drugs than doxorubicin. Specifically, the cluster was composed of homoharringtonine, mitoxantrone, ponatinib, romidepsin, belinostat, vorinostat, mitomycin C, mithramycin A and epirubicin. Among 29 types of sarcoma cells, one cell line of osteosarcoma (OS-#154) and both two cell lines of extraskeletal chondrosarcoma (CS-ExS-#66 and CS-ExS-#132) were shown to be chemotherapy-resistant phenotype. Nevertheless, homoharringtonine, mitoxantrone and ponatinib were shown to be commonly shared efficacy. These three agents were identified as potent suppressive drugs despite histological difference of sarcomas.

## Discussion

This study presented the pharmacological profiling of sarcomas, which leads to be found three commonly shared suppressive drugs to musculoskeletal tumors.

First, homoharringtonine is also known as omacetaxine, a protein

translation inhibitor derived from natural plant alkaloid, and have used for treatment of chronic myeloid leukemia. Homoharringtonine inhibits protein translation by preventing the initial elongation step of protein synthesis. In detail, homoharringtonine interacts with the ribosomes and prevents the correct positioning of amino acids of transported tRNAs [10]. Although clinical response has not been observed in solid tumors including malignant gliomas, melanoma, head and neck cancer, breast cancer, and colorectal cancer [11], the data depicted here implied an efficacy to sarcomas.

Secondly, mitoxantrone is one of the type II topoisomerase inhibitors, which intercalated with DNA and inhibition of protein synthesis, leading to inhibit the generation of topoisomerase II, which relaxes DNA coil at the time of transcription [12]. The mechanism of action is generally same as doxorubicin, which may be one of the reason mitoxantrone was selected as a considerable candidate in this study. Currently, based on a randomized clinical trial, mitoxantrone was used for relapsed acute lymphoblastic leukaemia [13]. With regard to solid tumors, several clinical studies reported in patients with sarcoma. In metastatic or recurrent leiomyosarcoma, no complete or partial responses have been observed [14]. Similarly, mitoxantrone have shown a negative efficacy to advanced sarcomas in phase II clinical trial [15]. In case of recurrent abdominal sarcomas, surgical excision of all gross disease and postoperative intraperitoneal chemotherapy with mitoxantrone presented a feasible treatment outcome with minimal toxicity, which may provide a survival benefit for patients [16]. Although there are some discrepancy between previous clinical results and the data presented in this study, mitoxantrone may show a satisfactory result in a considered chemotherapeutic regimen.

Third, ponatinib is known as one of multi-tyrosine kinase inhibitor, targeting at KIT, PDGFR $\alpha$ , VEGFR1, VEGFR2, BCR-ABL, RET, FLT3, SRC, FGFR1, FGFR2, FGFR3, and FGFR4 [17]. The result is supported by pazopanib, another multi-tyrosine kinase inhibitor, which currently offered to soft tissue sarcoma, similarly targeting at KIT, PDGFR $\alpha$ , PDGFR $\beta$ , VEGFR1, VEGFR2, VEGFR3 [18]. In comparison between these two drugs, KIT, PDGFR $\alpha$ , VEGFR1, and VEGFR2 were common targets. In addition, ponatinib may have a superiority to pazopanib because of wider range spectrum of targets such as FGFR1, FGFR2, FGFR3, FGFR4, RET, SRC, and FLT3. Based on these additional targets necessary to proliferation, ponatinib showed a comprehensive inhibitory effect in the data of pharmacological profile regardless of a variety of histological types in musculoskeletal tumors. Indeed, ponatinib has been used for refractory chronic myeloid/acute lymphoid leukemia. The drug now repositioned to therapeutic drug for sarcoma.

In conclusion, the new outlook suggests delivering a commonly shared therapeutic umbrella rather than histotype-tailored regimen in musculoskeletal tumors.

## Acknowledgment

We are grateful to the Dr. Tadashi Kondo (National Cancer Research institute, Tokyo, Japan) for permission to use sarcoma cell lines. The author would like to thank Mr. Satoshi Tada (Dynacom Co. Ltd. Chiba, Japan) for aiding with the bioinformatic analysis in this study.

## References

1. Nakajima, Kho, Yanagawa, Harazono, Hogan, Chen, et al. Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis. *Cancer Res.* 2016; 76:6: 1391-1402.
2. Nakajima, Kho, Yanagawa, Zimel, Heath, Hogan, et al. Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. *Cancer Metastasis Rev.* 2016; 35: 333-346.
3. Biermann, Chow, Reed, Lucas, Adkins, Agulnik, et al. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. *JNCCN.* 2017; 15: 155-167.
4. von Mehren, Randall, Benjamin, Boles, Bui, Casper, et al. Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines. *JNCCN;* 2014;12:473-483.
5. Casali, Blay. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21:198-203.
6. Hogendoorn, Athanasou, Bielack, Alava, Dei Tos, Ferrari, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21: 204-213.
7. Gronchi, Ferrari, Quagliuolo, Broto, Pousa, Grignani, U, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncol.* 2017; 18: 812-822.
8. Taylor, Barretina, Maki, Antonescu, Singer, Ladanyi. Advances in sarcoma genomics and new therapeutic targets. *Nat Rev Cancer.* 2011; 11: 541-557.
9. Gu, Eils, Schlesner. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics.* 2016; 32: 2847-2849.
10. Wetzler, Segal, Omacetaxine as an anticancer therapeutic: what is old is new again. *Curre pharmacol design.* 2011; 17: 59-64.
11. Kantarjian, Talpaz, Santini, Murgo, Cheson, O'Brien. Homoharringtonine: history, current research, and future direction. *Cancer.* 2011; 92: 1591-1605.
12. Kapuscinski, Darzynkiewicz. Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA, *Biochem pharmacol.* 1985; 34: 4203-4213.
13. Parker, Waters, Leighton, Hancock, Sutton, A Moorman, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. *Lancet.* 2010; 376: 2009-2017.
14. Muss, Bundy, Adcock, Beecham. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. *Am J Clin Oncol.* 1990; 13: 32-34.
15. Bull, Von Hoff, Balcerzak, Stephens, Panettiere. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. *Cancer Treat Rep.* 1985; 69: 231-233.
16. Eilber, Rosen, Forscher, Nelson, Dorey, Eilber. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. *Ann Surg Oncol.* 1999; 6: 645-650.
17. Tan, Putoczki, Stylli, Luwor. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. *Onco Targets Ther.* 2019; 12: 635-645.
18. van der Graaf, Blay, Chawla, Kim, Bui-Nguyen, Casali, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet.* 2012; 379: 1879-1886.